Abstract
Lung cancer is the number one cause of cancer-related mortality worldwide. To improve disease outcome, it is crucial to implement biomarkers into the clinics which assist physicians in their decisions regarding diagnosis, prognosis, as well as prediction of treatment response. Liquid biopsy offers an opportunity to obtain such biomarkers in a minimal invasive manner by retrieving tumor-derived material from body fluids of the patient. The abundance of circulating microRNAs is known to be altered in disease and has therefore been studied extensively as a cancer biomarker. Circulating microRNAs present a variety of favorable characteristics for application as liquid biopsy-based biomarkers, including their high stability, relatively high abundance, and presence is nearly all body fluids. Although the application of circulating microRNAs for the management of lung cancer has not entered the clinics yet, several studies showed their utility for diagnosis, prognosis, and efficacy prediction of various treatment strategies, including surgery, radio-/chemotherapy, as well as targeted therapy. To compensate for their limited tumor specificity, several microRNAs are frequently combined into microRNA panels. Moreover, the possibility to combine single microRNAs or microRNA panels with tumor imaging or other cancer-specific biomarkers has the potential to increase specificity and sensitivity and could lead to the clinical application of novel multi-marker combinations.
Sabrina Müller and Florian Janke contributed equally to this work.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aharonov R, Lebanony D, Benjamin H et al (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27:2030–2037
Ak G, Tomaszek SC, Kosari F et al (2015) MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int. https://doi.org/10.1155/2015/635748
Appierto V, Callari M, Cavadini E, Morelli D, Daidone MG, Tiberio P (2014) A lipemia-independent NanoDrop®-based score to identify hemolysis in plasma and serum samples. Bioanalysis 6:1215–1226
Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181–2190
Aushev VN, Zborovskaya IB, Laktionov KK, Girard N, Cros MP, Herceg Z, Krutovskikh V (2013) Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. PLoS One. 8(10):e78649. https://doi.org/10.1371/journal.pone.0078649
Baggish AL, Hale A, Weiner RB, Lewis GD, Systrom D, Wang F, Wang TJ, Chan SY (2011) Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J Physiol 589:3983–3994
Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’Olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP (2011) A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 3:495–503
Borchert GM, Lanier W, Davidson BL (2006) RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 13:1097–1101
Brase JC, Johannes M, Schlomm T, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616
Butz H, Kinga N, Racz K, Patocs A (2016) Circulating miRNAs as biomarkers for endocrine disorders. J Endocrinol Invest 39:1–10
Calin GA, Sevignani C, Dumitru CD et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci 101:2999–3004
Chang JY, Senan S, Paul MA et al (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637
Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006
Chen Q, Si Q, Xiao S, Xie Q, Lin J, Wang C, Chen L, Chen Q, Wang L (2013) Prognostic significance of serum miR-17-5p in lung cancer. Med Oncol 30:353
Chen X, Xu Y, Liao X et al (2016) Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumor Biol 37:11927–11936
Chin J, Syrek Jensen T, Ashby L, Hermansen J, Hutter JD, Conway PH (2015) Screening for lung cancer with low-dose CT—translating science into medicare coverage policy. N Engl J Med 372:2083–2085
Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B (2010) Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3:499–506
Cui E, Li H, Hua F, Wang B, Mao W, Feng X, Li J, Wang X (2012) Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin 34:309–313
Ding Y, Ma Q, Liu F, Zhao L, Wei W (2016) The potential use of salivary miRNAs as promising biomarkers for detection of cancer: a meta-analysis. PLoS ONE 11:1–12
Do Canto LM, Marian C, Willey S, Sidawy M, Da Cunha PA, Rone JD, Li X, Gusev Y, Haddad BR (2016) MicroRNA analysis of breast ductal fluid in breast cancer patients. Int J Oncol 48:2071–2078
Eldh M, Lötvall J, Malmhäll C, Ekström K (2012) Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. Mol Immunol 50:278–286
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386
Fortunato O, Boeri M, Verri C, Conte D, Mensah M, Suatoni P, Pastorino U, Sozzi G (2014) Assessment of circulating microRNAs in plasma of lung cancer patients. Molecules 19:3038–3054
Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GRR, Picciotto M, Russo A, Giordano A, Adamo V (2014) Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 229:97–99
Fromm B, Billipp T, Peck LE et al (2015) A uniform system for the annotation of vertebrate microRNA genes and the evolution of the human microRNAome. Annu Rev Genet 49:213–242
Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y (2012) miRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther 13:330–340
Goldstraw P, Chansky K, Crowley J et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer. J Thorac Oncol 11:39–51
Gui Y, Liu H, Zhang L, Lv W, Hu X (2015) Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 6:37043–37053
Han L, Witmer PD, Casey E, Valle D, Sukumar S (2007) DNA methylation regulates microRNA expression. Cancer Biol Ther 6:1284–1288
Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20:460–469
He L, He X, Lim LP et al (2007) A microRNA component of the p53 tumour suppressor network. Nature 447:1130–1134
He WJ, Li WH, Jiang B, Wang YF, Xia YX, Wang L (2015) MicroRNAs level as an initial screening method for early-stage lung cancer: a bivariate diagnostic random-effects meta-analysis. Int J Clin Exp Med 8:12317–12326
Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380
Hu Z, Chen X, Zhao Y et al (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721–1726
Hu H, Xu Z, Li C, Xu C, Lei Z, Zhang HT, Zhao J (2016) MiR-145 and miR-203 represses TGF-β-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells. Lung Cancer 97:87–94
Hunter MP, Ismail N, Zhang X et al (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One. 3(11):e3694. https://doi.org/10.1371/journal.pone.0003694
Jensen SG, Lamy P, Rasmussen MH, Ostenfeld MS, Dyrskjøt L, Ørntoft TF, Andersen CL (2011) Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics. https://doi.org/10.1186/1471-2164-12-435
Johnson CD, Esquela-Kerscher A, Stefani G et al (2007) The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67:7713–7722
Joosse SA, Pantel K (2015) Tumor-educated platelets as liquid biopsy in cancer patients. Cancer Cell 28:552–554
Jung M, Schaefer A, Steiner I, Kempkensteffen C, Stephan C, Erbersdobler A, Jung K (2010) Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem 56:998–1006
Kannan M, Atreya C (2010) Differential profiling of human red blood cells during storage for 52 selected microRNAs. Transfusion 50:1581–1588
Khalil F, Ali-labib R, Hassan I, Moustafa H (2017) MicroRNA-155 expression in exhaled breath condensate of patients with lung cancer. Egypt J Chest Dis Tuberc 66:687–691
Kim DJ, Linnstaedt S, Palma J et al (2012a) Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagnostics 14:71–80
Kim YK, Yeo J, Kim B, Ha M, Kim VN (2012b) Short structured RNAs with low GC content are selectively lost during extraction from a small number of cells. Mol Cell 46:893–895
Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G (2011) Haemolysis during sample preparation alters microRNA content of plasma. PLoS One. 8(9):e24145. https://doi.org/10.1371/journal.pone.0024145
Kroh EM, Parkin RK, Mitchell PS, Tewari M (2010) Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50:298–301
Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11:597–610
Le HB, Zhu WY, Chen DD, He JY, Huang YY, Liu XG, Zhang YK (2012) Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med Oncol 29:3190–3197
Leidinger P, Galata V, Backes C, Stähler C, Rheinheimer S, Huwer H, Meese E, Keller A (2015) Longitudinal study on circulating miRNAs in patients after lung cancer resection. Oncotarget 6:16674–16685
Leng Q, Lin Y, Jiang F, Lee C-J, Zhan M, Fang H, Wang Y, Jiang F (2017) A plasma miRNA signature for lung cancer early detection 8:111902–111911
Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20
Li Y, Li W, Ouyang Q, Hu S, Tang J (2011) Detection of lung cancer with blood microRNA-21 expression levels in Chinese population. Oncol Lett 2:991–994
Li C, Hashimi SM, Good DA, Cao S, Duan W, Plummer PN, Mellick AS, Wei MQ (2012) Apoptosis and microRNA aberrations in cancer. Clin Exp Pharmacol Physiol 39:739–746
Li Z-H, Zhang H, Yang Z-G, Wen G-Q, Cui Y-B, Shao G-G (2013) Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer. J Int Med Res 41:1437–1444
Li B, Ren S, Li X et al (2014a) MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer 83:146–153
Li J, Li X, Ren S et al (2014b) miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget 5:7902–7916
Li W, Wang Y, Zhang Q et al (2015) MicroRNA-486 as a biomarker for early diagnosis and recurrence of non-small cell lung cancer. PLoS One. 10(8):e0134220. https://doi.org/10.1371/journal.pone.0134220
Lin Q, Chen T, Lin Q, Lin G, Lin J, Chen G, Guo L (2013) Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer. J Surg Oncol 107:767–771
Lu J, Getz G, Miska EA et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838
Lujambio A, Calin GA, Villanueva A et al (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105:13556–13561
Ma W, Ma C, Zhou N, Li X, Zhang Y (2016) Up- regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy. Sci Rep 6:31651
MacFarlane L-A, Murphy PR (2010) MicroRNA: biogenesis, function and role in cancer. Curr Genomics 11:537–561
Martin J, Ginsberg RJ, Venkatraman ES, Bains MS, Downey RJ, Korst RJ, Kris MG, Rusch VW (2002) Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 20:1989–1995
Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, Ginsberg RJ (1995) Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120–129
McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A (2011) Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57:833–840
Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, Vandesompele J (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. https://doi.org/10.1186/gb-2009-10-6-r64
Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci 105:10513–10518
Moldovan L, Batte K, Wang Y, Wisler J, Piper M (2013) Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR. Circulating MicroRNAs 1024:1–15
Müller V, Gade S, Steinbach B et al (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat 147:61–68
Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer DG, Chen G (2015) A Novel serum 4-microRNA signature for lung cancer detection. Sci Rep. https://doi.org/10.1038/srep12464
Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WEE, Van Meerbeeck J, Rami-Porta R (2016) The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the tnm classification for lung cancer. J Thorac Oncol 11:300–311
Nishikawa E, Osada H, Okazaki Y et al (2011) MiR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res 71:6165–6173
Ohtsuka M, Ling H, Doki Y, Mori M, Calin G (2015) MicroRNA processing and human cancer. J Clin Med 4:1651–1667
Osada H, Takahashi T (2011) let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 102:9–17
Padda SK, Burt BM, Trakul N, Wakelee HA (2014) Early-stage non-small cell lung cancer: surgery, stereotactic radiosurgery, and individualized adjuvant therapy. Semin Oncol 41:40–56
Pasquinelli AE, Reinhart BJ, Slack F et al (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 408:86–89
Peltier HJ, Latham GJ (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14:844–852
Peng Y, Croce CM (2016) The role of MicroRNAs in human cancer. Sig Transduct Target Ther 1:15004
Pöttgen C, Eberhardt W, Grannass A et al (2007) Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 25:4987–4992
Pritchard CC, Cheng HH, Tewari M (2012) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13:358–369
Robles AI, Arai E, Mathé EA et al (2015) An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol 10:1037–1048
Saito Y, Jones PA (2006) Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5:2220–2222
Sakashita S, Sakashita M, Sound Tsao M (2014) Genes and pathology of non-small cell lung carcinoma. Semin Oncol 41:28–39
Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, Viktorsson K, Zhivotovsky B (2012) miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer 107:1361–1373
Sanfiorenzo C, Ilie MI, Belaid A, Barlési F, Mouroux J, Marquette CH, Brest P, Hofman P (2013) Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One. https://doi.org/10.1371/journal.pone.0054596
Schwarzenbach H, Hoon DSB, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437
Schwarzenbach H, Da Silva AM, Calin G, Pantel K (2015) Data normalization strategies for microRNA quantification. Clin Chem 61:1333–1342
Sculier J-P, Moro-Sibilot D (2009) First- and second-line therapy for advanced nonsmall cell lung cancer. Eur Respir J Off J Eur Soc Clin Respir Physiol 33:915–930
Shah JS, Soon PS, Marsh DJ (2016) Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS One 11(4):e0153200. https://doi.org/10.1371/journal.pone.0153200
Shen J, Liu Z, Todd NW et al (2011) Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11:374
Shen Y, Tang D, Yao R, Wang M, Wang Y, Yao Y, Li X, Zhang H (2013) MicroRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation. Med Oncol. https://doi.org/10.1007/s12032-013-0750-1
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30
Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531–548
Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z (2012) Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 57:897–904
Sozzi G, Boeri M, Rossi M et al (2014) Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 32:768–773
Strebhardt K, Ullrich A (2008) Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473–480
Sun Y, Hawkins PG, Bi N et al (2017) Serum microRNA signature predicts response to high-dose radiation therapy in locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 100:107–114
Takeyama Y, Sato M, Horio M et al (2010) Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Lett 296:216–224
ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R (2017) Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med 14:1–24
Tian F, Han Y, Yan X, Zhong D, Yang G, Lei J, Li X, Wang X (2016) Upregulation of microRNA-451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis. Thorac Cancer 7:226–231
Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V (2015) Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. https://doi.org/10.1155/2015/731479
Tokumaru S, Suzuki M, Yamada H, Nagino M, Takahashi T (2008) let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis 29:2073–2077
Travis WD, Brambilla E, Riely GJ (2013) New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31:992–1001
Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, Rosser CJ, Goodison S (2016) A microRNA biomarker panel for the non-invasive detection of bladder cancer. Oncotarget 7(52):86290–86299
Vasudevan S, Tong Y, Steitz JA (2007) Switching from repression to activation: MicroRNAs can up-regulate translation. Science 80(318):1931–1934
Veronesi G, Bellomi M, Mulshine JL et al (2008) Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for baseline lung nodules. Lung Cancer 61:340–349
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–435
Wang G-K, Zhu J-Q, Zhang J-T, Li Q, Li Y, He J, Qin Y-W, Jing Q (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666
Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS One 7(7):e41561. https://doi.org/10.1371/journal.pone.0041561
Wang Y, Gu J, Roth JA, Hildebrandt MAT, Lippman SM, Ye Y, Minna JD, Wu X (2013) Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res 73:4801–4809
Wang H, Wu S, Zhao L, Zhao J, Liu J, Wang Z (2015a) Clinical use of microRNAs as potential non-invasive biomarkers for detecting non-small cell lung cancer: a meta-analysis. Respirology 20:56–65
Wang S, Su X, Bai H et al (2015b) Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. J Hematol Oncol. https://doi.org/10.1186/s13045-015-0210-9
Wang Y, Zhao H, Gao X et al (2016) Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma. Oncotarget 7:26070–26086
Westeel V, Choma D, Clément F, Woronoff-Lemsi MC, Pugin JF, Dubiez A, Depierre A (2000) Relevance of intensive postoperative follow-up after surgery for non-small cell lung cancer. Ann Thorac Surg 70:1185–1190
Wu R, Jiang Y, Wu Q, Li Q, Cheng D, Xu L, Zhang C, Zhang M, Ye L (2014) Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies. Tumor Biol 35:8829–8836
Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, Alattar M, Deepak J, Stass SA, Jiang F (2011) Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67:170–176
Xu X, Yu S, Sun W et al (2018) miRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment. J Cancer Res Clin Oncol 144:431–438
Yanaihara N, Caplen N, Bowman E et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198
Yu SL, Chen HY, Chang GC et al (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13:48–57
Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL, Jiang F (2010) Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 127:2870–2878
Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH (2010) MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 411:846–852
Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B (2013) Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. PLoS One. 8(11):e81408. https://doi.org/10.1371/journal.pone.0081408
Zhang H, Mao F, Shen T, Luo Q, Ding Z, Qian L, Huang J (2017) Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett 13:669–676
Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18:350–359
Zhu J, Qi Y, Wu J, Shi M, Feng J, Chen L (2016a) Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum. Oncol Lett 12:4829–4837
Zhu WY, Zhou KY, Zha Y, Chen DD, He JY, Ma HJ, Liu XG, Le HB, Zhang YK (2016b) Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. PLoS ONE 11:1–16
Acknowledgements
We thank Sabine Klauck for critical reading of the manuscript and valuable comments.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Müller, S., Janke, F., Dietz, S., Sültmann, H. (2020). Circulating MicroRNAs as Potential Biomarkers for Lung Cancer. In: Schaffner, F., Merlin, JL., von Bubnoff, N. (eds) Tumor Liquid Biopsies. Recent Results in Cancer Research, vol 215. Springer, Cham. https://doi.org/10.1007/978-3-030-26439-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-030-26439-0_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-26438-3
Online ISBN: 978-3-030-26439-0
eBook Packages: MedicineMedicine (R0)